Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Journal of Clinical Oncology · 10.07.2025 · 43 (20) · 2276-2284
DOI: 10.1200/jco-25-00690 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2025. Verfasst von Michael Wang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL. METHODS Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m 2 once daily; days 1 and 2) and rituximab (375 mg/m 2 as a single dose; day 1) followed by rituximab maintenance in responding patients for 2 years. Crossover to acalabrutinib at disease progression was permitted. The primary end point was PFS per the independent review committee; overall response rate and OS were secondary end points. RESULTS In total, 598 patients were randomly assigned, with 299 in each arm. At a median follow-up of 49.8 months using the reverse Kaplan-Meier method, the median PFS was 66.4 months in the acalabrutinib arm and 49.6 months in the placebo arm (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.94]; P = .0160). Benefit was seen across all subgroups, including those with high-risk features. Overall response/complete response rates were 91.0%/66.6% and 88.0%/53.5% in the acalabrutinib and placebo arms, respectively. OS was not significantly different (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27). Grade 3 or greater adverse events were reported in 88.9% and 88.2% in the acalabrutinib and placebo arms, respectively. CONCLUSION The combination of acalabrutinib with bendamustine-rituximab significantly improved PFS. Clinical benefit of acalabrutinib with bendamustine-rituximab was achieved with manageable toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX.
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
- 4th Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
- Key Laboratory of Carcinogenesis and Translational Research, Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
- Pratia MCM Maków, Krakow, Poland.
- Department of Clinical Oncology, MSC National Research Institute of Oncology, Krakow, Poland.
ORCID-Profile: Michael Wang, Brad S Kahl, Jonas Paludo, Chan Y Cheah, Marta Morawska, Juan-Manuel Sancho, Cecily Forsyth, Martin Dreyling
Zitieren
APA
Wang, M., Salek, D., Belada, D., Song, Y., Jurczak, W., Kahl, B. S., Paludo, J., Chu, M. P., Kryachok, I., Fogliatto, L., Cheah, C. Y., Morawska, M., Sancho, J. M., Li, Y., Patti, C., Forsyth, C., Zhang, J., Lesley, R., Ramadan, S., …, & ECHO Investigators (2025). Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. Journal of Clinical Oncology, 43(20), 2276-2284. https://doi.org/10.1200/jco-25-00690
Vancouver
Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, et al. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. Journal of Clinical Oncology. 2025;43(20):2276-2284. doi:10.1200/jco-25-00690
BibTeX
@article{Wang2025,
author = {Wang, Michael and Salek, David and Belada, David and Song, Yuqin and Jurczak, Wojciech and Kahl, Brad S and Paludo, Jonas and Chu, Michael P and Kryachok, Iryna and Fogliatto, Laura and Cheah, Chan Y and Morawska, Marta and Sancho, Juan-Manuel and Li, Yufu and Patti, Caterina and Forsyth, Cecily and Zhang, Jingyang and Lesley, Robin and Ramadan, Safaa and Rule, Simon and Dreyling, Martin and ECHO investigators, ECHO investigators and ECHO Investigators, ECHO Investigators},
title = {Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {20},
pages = {2276--2284},
doi = {10.1200/jco-25-00690}
}
EUVIMED